ELAN Stock Overview
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Elanco Animal Health Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.44 |
| 52 Week High | US$18.80 |
| 52 Week Low | US$11.40 |
| Beta | 1.42 |
| 11 Month Change | 6.50% |
| 3 Month Change | -8.01% |
| 1 Year Change | 12.66% |
| 33 Year Change | -56.35% |
| 5 Year Change | -51.78% |
| Change since IPO | -62.67% |
Recent News & Updates
Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals
Nov 15
Elanco Animal Health: Not Expensive, But Debt Remains An Issue
Nov 08Recent updates
Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals
Nov 15Elanco Animal Health: Not Expensive, But Debt Remains An Issue
Nov 08Here's Why Elanco Animal Health (NYSE:ELAN) Has A Meaningful Debt Burden
Sep 22Elanco Animal Health Incorporated (NYSE:ELAN) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Sep 01Elanco Animal Health: Positioned For Success
Aug 16Investors Don't See Light At End Of Elanco Animal Health Incorporated's (NYSE:ELAN) Tunnel And Push Stock Down 27%
Jul 11Elanco Animal Health: Pipeline Concerns Appear Overblown
Jun 30Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet
Jun 06Elanco Animal Health: At Least Fully Valued After Rally
Jun 05Benign Growth For Elanco Animal Health Incorporated (NYSE:ELAN) Underpins Its Share Price
Apr 22Elanco Animal Health (NYSE:ELAN) Seems To Be Using A Lot Of Debt
Feb 24Elanco Animal Health: A Solid Sale Addresses Leverage
Feb 09Elanco Animal Health Incorporated (NYSE:ELAN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 01Elanco Animal Health: Turning More Healthy
Dec 21Is Elanco Animal Health (NYSE:ELAN) A Risky Investment?
Nov 09Elanco Animal Health: Signs Of Stabilization, Amidst Still A Big Debt Pile
Oct 05Here's Why Elanco Animal Health (NYSE:ELAN) Is Weighed Down By Its Debt Load
Aug 02Elanco Animal Health: Seems Like A Decent Bet Right Now
Jul 25Elanco Animal Health: Robust Results Overshadowed By Persisting Challenges
Jul 14There's No Escaping Elanco Animal Health Incorporated's (NYSE:ELAN) Muted Revenues
Jun 09Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet
Feb 22Elanco Q4 2022 Earnings Preview
Feb 20Elanco's Tangible Equity Units: Living With The Worst Case
Dec 13We Think Elanco Animal Health (NYSE:ELAN) Is Taking Some Risk With Its Debt
Nov 08Elanco Q3 2022 Earnings Preview
Nov 07Elanco Animal Health: This 'Sick Dog' Should Recover
Oct 19Shareholder Returns
| ELAN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.3% | -5.3% | -1.2% |
| 1Y | 12.7% | 8.7% | 30.4% |
Return vs Industry: ELAN exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: ELAN underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| ELAN volatility | |
|---|---|
| ELAN Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ELAN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ELAN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 9,550 | Jeff Simmons | www.elanco.com |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.
Elanco Animal Health Incorporated Fundamentals Summary
| ELAN fundamental statistics | |
|---|---|
| Market cap | US$6.58b |
| Earnings (TTM) | US$205.00m |
| Revenue (TTM) | US$4.45b |
32.4x
P/E Ratio1.5x
P/S RatioIs ELAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELAN income statement (TTM) | |
|---|---|
| Revenue | US$4.45b |
| Cost of Revenue | US$2.02b |
| Gross Profit | US$2.44b |
| Other Expenses | US$2.23b |
| Earnings | US$205.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 54.74% |
| Net Profit Margin | 4.60% |
| Debt/Equity Ratio | 66.8% |
How did ELAN perform over the long term?
See historical performance and comparison